Health Claims Based On Varying Levels Of Evidence Need Distinctions - FDA
This article was originally published in The Tan Sheet
Executive Summary
An issue FDA aims to address at the April 4 public meeting on implementation of the Pearson v. Shalala court decision is how best to convey to consumers that certain dietary supplement health claims do not have as much scientific support as other claims.
You may also be interested in...
FDA Pearson Implementation Faces Further Congressional Criticism
FDA's progress in implementing the Pearson v. Shalala court decision is sharply criticized by Republican Reps. Helen Chenoweth-Hage (Idaho), Ron Paul (Texas) and Bob Stump (Ariz.) in a March 17 letter to the agency.
FDA Pearson Implementation Faces Further Congressional Criticism
FDA's progress in implementing the Pearson v. Shalala court decision is sharply criticized by Republican Reps. Helen Chenoweth-Hage (Idaho), Ron Paul (Texas) and Bob Stump (Ariz.) in a March 17 letter to the agency.
FDA Pearson Implementation Faces Further Congressional Criticism
FDA's progress in implementing the Pearson v. Shalala court decision is sharply criticized by Republican Reps. Helen Chenoweth-Hage (Idaho), Ron Paul (Texas) and Bob Stump (Ariz.) in a March 17 letter to the agency.